Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label spesolimab extension in fistulising Crohn's disease
NL-OMON52849Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Primary endpoint: Exposure adjusted rate of patients reporting a treatment emergent adverse event. Started Dec 2021; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON52849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52849.